Duchenne muscular dystrophy is a rare genetic disorder that causes muscles to slowly break down over time, leading to symptoms such as difficulty walking. Dysfunction of the muscle stabilizing protein dystrophin is the primary cause of the disease. The biotech company MyoGeneBio uses CRISPR gene editing to restore partial function of dystrophin to minimize symptoms and slow the progression of disease.
Download the infographic: CRISPR editing for treating Duchenne muscular dystrophy
